BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 10346008)

  • 1. PSO vs. HMO: some pros and cons of entering the Medicare-risk market.
    Coile RC
    Healthc Strateg; 1998 Aug; 2(8):10-2. PubMed ID: 10346008
    [No Abstract]   [Full Text] [Related]  

  • 2. What will it take to become a PSO?
    Russ Coiles Health Trends; 1998 Jun; 10(8):9-12. PubMed ID: 10185909
    [No Abstract]   [Full Text] [Related]  

  • 3. Provider-sponsored organizations: the state of the market.
    Francoeur A; Tompkins RK
    Manag Care Interface; 1999 Jun; 12(6):78-82. PubMed ID: 10538465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Provider-sponsored plans reveal keys to survival.
    Public Sect Contract Rep; 1999 Mar; 5(3):33-8. PubMed ID: 10351420
    [No Abstract]   [Full Text] [Related]  

  • 5. HMO provider networks in Medicare+Choice: comparing Medicare and commercial lines of business.
    Lake T; Gold M; Hurley R
    Manag Care Q; 2001; 9(4):16-22. PubMed ID: 11813453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Provider sponsored organizations: a critical assessment.
    Hirsch WR
    J Cardiovasc Manag; 1998; 9(4):10-1. PubMed ID: 10185101
    [No Abstract]   [Full Text] [Related]  

  • 7. Marketing and finance issues in provider-sponsored Medicare HMOs.
    Laleman M; Scibilia K
    Healthc Strateg; 1998 Mar; 2(3):1-6. PubMed ID: 10345999
    [No Abstract]   [Full Text] [Related]  

  • 8. Despite Medicare+Choice changes, rural providers cautious about risk.
    Public Sect Contract Rep; 1998 Oct; 4(10):149-52. PubMed ID: 10187167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Medicare+Choice program.
    Fuchs B
    Bull Am Coll Surg; 1998 Dec; 83(12):8-12. PubMed ID: 10344972
    [No Abstract]   [Full Text] [Related]  

  • 10. Senior community blazes trail as Medicare risk provider.
    Public Sect Contract Rep; 1999 Feb; 5(2):17-21. PubMed ID: 10346533
    [No Abstract]   [Full Text] [Related]  

  • 11. Use financial analysts' methods to assess the strength to Medicare risk plans.
    Public Sect Contract Rep; 1998 Oct; 4(10):157-9, 145. PubMed ID: 10187170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PSO option.
    Weronka WA
    Healthplan; 1999; 40(4):73-4, 76-8. PubMed ID: 10557740
    [No Abstract]   [Full Text] [Related]  

  • 13. Provider-owned health plans: El Dorado or Armageddon?
    McCarthy EJ
    Healthc Financ Manage; 1999 Nov; 53(11):35-8. PubMed ID: 11066679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Providers not rushing onto PSO bandwagon.
    Capitation Manag Rep; 1999 Jan; 6(1):9-12. PubMed ID: 10345981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicare program; solvency standards for provider-sponsored organizations. Health Care Financing Administration (HCFA), HHS. Final rule.
    Fed Regist; 1999 Dec; 64(245):71673-8. PubMed ID: 11010686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heading for the exits? At a time when major and regional health plans are abandoning risk contracts ...
    Med Netw Strategy Rep; 1998 Nov; 7(11):1-7. PubMed ID: 10339080
    [No Abstract]   [Full Text] [Related]  

  • 17. Why provider-sponsored health plans don't work.
    Burns LR; Thorpe DP
    Healthc Financ Manage; 2001; Suppl():12-6. PubMed ID: 11155280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managed Medicare at the crossroads.
    Parsons DW
    Eff Clin Pract; 1999; 2(1):47-8. PubMed ID: 10346554
    [No Abstract]   [Full Text] [Related]  

  • 19. PSO organizers find big I.T. investments essential.
    McCormack J
    Health Data Manag; 1998 Sep; 6(9):105-6, 108. PubMed ID: 10185223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSOs: what happened?
    Dalzell MD
    Manag Care; 1998 Nov; 7(11):26-8, 30-2. PubMed ID: 10187125
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.